|Classification and external resources|
|Patient UK||Pleural empyema|
Pleural empyema, also known as pyothorax or purulent pleuritis, is empyema (an accumulation of pus) in the pleural cavity that can develop when bacteria invade the pleural space, usually in the context of a pneumonia. It is one of various kinds of pleural effusion. There are three stages: exudative, when there is an increase in pleural fluid with or without the presence of pus; fibrinopurulent, when fibrous septa form localized pus pockets; and the final organizing stage, when there is scarring of the pleura membranes with possible inability of the lung to expand. Simple pleural effusions occur in up to 40% of bacterial pneumonias. They are usually small and resolve with appropriate antibiotic therapy. If however an empyema develops additional intervention is required.
The incidence of pleural empyema and the prevalence of specific causative microorganisms varies depending on the source of infection (community acquired vs. hospital acquired pneumonia), the age of the patient and host immune status. Risk factors include alcoholism, drug use, HIV infection, neoplasm and pre-existent pulmonary disease. Pleural empyema was found in 0.7% of 3675 patients needing hospitalization for a community acquired pneumonia in a recent Canadian single-center prospective study. A multi-center study from the UK including 430 adult patients with community acquired pleural empyema found negative pleural-fluid cultures in 54% of patients, Streptococcus milleri group in 16%, Staphylococcus aureus in 12%, Streptococcus pneumoniae in 8%, other Streptococci in 7% and anaerobic bacteria in 8%. Given the difficulties in culturing anaerobic bacteria the frequency of the latter (including mixed infections) might be underestimated.
The risk of empyema in children seems to be comparable to adults. Using the United States Kids’ Inpatient Database the incidence is calculated to be around 1.5% in children hospitalized for community acquired pneumonia, although percentages up to 30% have been reported in individual hospitals, a difference which may be explained by an transient endemic of highly invasive serotype or overdiagnosis of small parapneumonic effusions. The distribution of causative organisms does differ greatly from that in adults: in an analysis of 78 children with community acquired pleural empyema, no micro-organism was found in 27% of patients, Streptococcus pneumoniae in 51%, Streptococcus pyogenes in 9% and Staphylococcus aureus in 8%.
Although pneumococcal vaccination dramatically decreased the incidence of pneumonia in children, it did not have this effect on the incidence of complicated pneumonia. It has been shown that the incidence of empyema in children was already on the rise at the end of the 20th century, and that the widespread use of pneumococcal vaccination did not slow down this trend. This might in part be explained by a change in prevalence of (more invasive) pneumococcal serotypes, some of which are not covered by the vaccine, as well a rise in incidence of pneumonia caused by other streptococci and staphylococci. The incidence of empyema seems to be rising in the adult population as well, albeit at a slower rate.
The clinical presentation of both the adult and pediatric patient with pleural empyema depends upon several factors, including the causative micro-organism. Most cases present themselves in the setting of a pneumonia, although up to one third of patients do not have clinical signs of pneumonia and as many as 25% of cases is associated with trauma (including surgery). Typical symptoms include cough, chest pain, shortness of breath and fever.
The initial investigations for suspected empyema remains chest X-ray, although it cannot differentiate an empyema from uninfected parapneumonic effusion. Ultrasound must be used to confirm the presence of a pleural fluid collection and can be used to estimate the size of the effusion, differentiate between free and loculated pleural fluid and guide thoracocentesis if necessary. Chest CT and MRI do not provide additional information in most cases and should therefore not be performed routinely.
The most often used "golden" criteria for empyema are pleural effusion with macroscopic presence of pus, a positive Gram stain or culture of pleural fluid, or a pleural fluid pH under 7.2 with normal peripheral blood pH. Clinical guidelines for adult patients therefore advocate diagnostic pleural fluid aspiration in patients with pleural effusion in association with sepsis or pneumonic illness. Because pleural effusion in the pediatric population is almost always parapneumonic and the need for chest tube drainage can be made on clinical grounds, British guidelines for the management of pleural infection in children do not recommend diagnostic pleural fluid sampling.
Blood and sputum culture has often already been performed in the setting of community acquired pneumonia needing hospitalization. It should however be noted that the micro-organism responsible for development of empyema is not necessarily the same as the organism causing the pneumonia, especially in adults. As already mentioned before, sensitivity of pleural fluid culture is generally low, often partly due to prior administration of antibiotics. It has been shown that culture yield can be increased from 44% to 69% if pleural fluid is injected into blood culture bottles (aerobic and anaerobic) immediately after aspiration. Furthermore, diagnostic rates can be improved for specific pathogens using polymerase chain reaction or antigen detection, especially for Streptococcus pneumoniae, Streptococcus pyogenes and Staphylococcus aureus. In a study including 78 children with pleural empyema, the causative micro-organism could be identified using direct culture of fresh pleural fluid in 45% of patients, with an additional 28% using PCR on pleural fluid of negative cultures. Pneumococcal antigen detection in pleural fluid samples by latex agglutination can also be useful for rapid diagnosis of pneumococcal empyema. In the previously noted study, positive and negative predictive value of pneumococcal antigen detection was 95% and 90%, respectively. However, despite the additional diagnostic value of these tests, PCR and antigen detection have limited value in determining treatment choice because of the lack of information on antibiotic resistance.
Pleural fluid drainage
Proven empyema (as defined by the "golden" criteria mentioned earlier) is an indication for prompt chest tube drainage. This has been shown to improve resolution of the infection and shorten hospital admission. Data from a meta-analysis has shown that a pleural fluid pH of <7.2 is the most powerful indicator to predict the need for chest tube drainage in patients with non-purulent, culture negative fluid. Other indications for drainage include poor clinical progress during treatment with antibiotics alone and patients with a loculated pleural collection.
Because of the viscous, lumpy nature of infected pleural fluid, in combination with possible septation and loculation, it has been proposed that intrapleural fibrinolytic or mucolytic therapy might improve drainage and therefore might have a positive effect on the clinical outcome. However, a well powered randomized controlled trial found no reduction in mortality or the need for surgery in patients who were given an intrapleural fibrinolytic agent (streptokinase) compared to placebo. Another recent randomized controlled trial did find a reduction in the need for surgery and a shorter hospital stay in patients treated with both a fibrinolytic agent (tissue plasminogen activator) and a mucolytic agent (DNase) compared to placebo or single use of either agent.
Approximately 15 to 40 percent of patients require surgical drainage of the infected pleural space because of inadequate drainage due to clogging of the chest tube or loculated empyema. Patients should thus be considered for surgery if they have ongoing signs of sepsis in association with a persistent pleural collection despite drainage and antibiotics. Video-assisted thoracoscopic surgery (VATS) is used as a first-line therapy in many hospitals, although open thoracic drainage remains a frequently used alternative technique.
There is no readily available evidence on the route of administration and duration of antibiotics in patients with pleural empyema. Experts agree that all patients should be hospitalized and treated with antibiotics intravenously. The specific antimicrobial agent should be chosen based on Gram stain and culture, or on local epidemiologic data when these are not available. Anaerobic coverage must be included in all adults, and in children if aspiration is likely. Good pleural fluid and empyema penetration has been reported in adults for penicillins, ceftriaxone, metronidazole, clindamycin, vancomycin, gentamycin and ciprofloxacin. Aminoglycosides should be avoided as they have poor penetration into the pleural space. There is no clear consensus on duration of intravenous and oral therapy. Switching to oral antibiotics can be considered upon clinical and objective improvement (adequate drainage and removal of chest tube, declining CRP, temperature normalization). Oral antibiotic treatment should then be continued for another 1–4 weeks, again based on clinical, biochemical and radiological response.
All patients with empyema require outpatient follow-up with a repeat chest X-ray and inflammatory biochemistry analysis within 4 weeks following discharge. Chest radiograph returns to normal in the majority of patients by 6 months. Patients should of course be advised to return sooner if symptoms redevelop. Long-term sequelae of pleural empyema are rare but include bronchopleural fistula formation, recurrent empyema and pleural thickening, which may lead to functional lung impairment needing surgical decortication.
Approximately 15% of adult patients with pleural infection die within 1 year of the event, although deaths are usually due to comorbid conditions and not directly due to sepsis from the empyema. Mortality in children is generally reported to be less than 3%. No reliable clinical, radiological or pleural fluid characteristics accurately determine patients’ prognosis at initial presentation.
- Alfageme I, Munoz F, Pena N, Umbria S. "Empyema of the thorax in adults. Etiology, microbiologic findings, and management". Chest 1993; 103(3):839-43
- Ahmed R, Marri T, Huang J. "Thoracic empyema in patients with community-acquired pneumonia". American Journal of Medicine 2006; 119(10):877-83
- Maskell NA, Davies CWH, Nunn AJ, Hedley EL, Gleeson FV, Miller R, Gabe R, Rees GL, Peto TEA, Woodhead MA, Lane DJ, Darbyshire JH, Davies RJO. "U.K. controlled trial of intrapleural streptokinase for pleural infection". New England Journal of Medicine 2005; 352(9):865-74
- Li S, Tancredi D. "Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine". Pediatrics 2010; 125(1):26-33
- Byington CL, Spencer LY, Johnson TA, Pavia AT, Allen D, Mason EO, Kaplan S, Carroll KC, Daly JA, Christenson JC, Samore MH. "An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations". Clinical Infectious Diseases 2002; 34(4):434-40
- Le Monnier A, Carbonnelle E, Zahar JR, Le Bourgeois M, Abachin E, Quesne G, Varon E, Descamps P, De Blic J, Scheinmann P, Berche P, Ferroni A. "Microbiological diagnosis of empyema in children: comparative evaluations by culture, polymerase chain reaction, and pneumococcal antigen detection in pleural fluids". Clinical Infectious Diseases 2006; 42(8):1135-40
- Grijalva CG, Nuorti JP, Zhu Y, Griffin MR. "Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States". Clinical Infectious Diseases 2010; 50(6):805-13
- Obando I, Camacho-Lovillo MS, Porras A, Gandía-González MA, Molinos A, Vazquez-Barba I, Morillo-Gutierrez B, Neth OW, Tarrago D. "Sustained high prevalence of pneumococcal serotype 1 in paediatric parapneumonic empyema in southern Spain from 2005 to 2009". Clinical Microbiology and Infection 2012; 18(8):763-8
- Fernandez-Cotarelo MJ, Lopez-Medrano F, San, Juan R, Az-Pedroche C, Lizasoain M, Chaves F, Aguado JM, San Juan R, Diaz-Pedroche C. "Protean manifestations of pleural empyema caused by Streptococcus pneumoniae in adults". European Journal of Internal Medicine 2007; 18:141-5
- King S, Thomson A. "Radiological perspectives in empyema". British Medical Bulletin 2002; 61:203-14
- Balfour-Lynn IM, Abrahamson E, Cohen G, Hartley J, King S, Parikh D, Spencer D, Thomson AH, Urquhart D. "BTS guidelines for the management of pleural infection in children". Thorax 2005; 60(Suppl 1):1-21
- Ferrer A, Osset J, Alegre J, Suriñach JM, Crespo E, Fernández de Sevilla T, Fernández F. "Prospective clinical and microbiological study of pleural effusions". European Journal of Clinical Microbiology and Infectious Diseases 1999; 18(4):237-41
- Davies H, Davies R, Davies C. "Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010". Thorax 2010; 65(Suppl 2):41-53
- Sasse S, Nguyen TK, Mulligan M, Wang NS, Mahutte CK, Light RW. "The effects of early chest tube placement on empyema resolution". Chest 1997; 111(6):1679-83
- Heffner JE, Brown LK, Barbieri C, DeLeo JM. "Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis". American Journal of Respiratory Critical Care Medicine 1995; 151(6):1700-8
- Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, Peckham D, Davies CWH, Ali N, Kinnear W, Bentley A, Kahan BC, Wrightson JM, Davies HE, Hooper CE, Lee Y C, Hedley EL, Crosthwaite N, Choo L, Helm EJ,Gleeson FV, Nunn AJ, Davies RJO. "Intrapleural use of tissue plasminogen activator and DNase in pleural infection". New England Journal of Medicine 2011; 365(6):518-26
- Ferguson AD, Prescott RJ, Selkon JB, Watson D, Swinburn CR. "The clinical course and management of thoracic empyema". Quarterly Journal of Medicine 1996; 89(4):285-9
- Teixeira LR, Sasse SA, Villarino MA, Nguyen T, Mulligan ME, Light RW. "Antibiotic levels in empyemic pleural fluid". Chest 2000; 117(6):1734-9
- Umut S, Demir T, Akkan G, Keskiner N, Yilmaz V, Yildrim N, Sipahioglu B, Hasan A, Barlas A, Sozer K, Ozuner Z. "Penetration of ciprofloxacin into pleural fluid". Journal of Chemotherapy 1993; 5(2):110-2
- Davies CW, Kearney SE, Gleeson FV, Davies RJ. "Predictors of outcome and long-term survival in patients with pleural infection". American Journal of Respiratory and Critical Care Medicine 1999; 160(5-1):1682-7